Search

Your search keyword '"Balleari, E."' showing total 236 results

Search Constraints

Start Over You searched for: Author "Balleari, E." Remove constraint Author: "Balleari, E."
236 results on '"Balleari, E."'

Search Results

1. Topic: AS09-Quality of life-Disease experiences: EXPLORING UNMET NEEDS OF MDS PATIENTS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY

2. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes

5. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

11. Different Repo Doses (High vs Standard) for Treatment of Anemia in MDS Patients: A Survey from the Italian MDS Registry

12. MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System

13. A Real-Life Study of Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes

14. Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study

15. Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents

17. Anagrelide in Essential Thrombocythemia: a retrospettive study'

18. Androgen metabolism and inhibition of interleukin-1 synthesis in primary cultured human synovial macrophages

23. 147 IN VITRO CULTURE OF BM CELLS AND CYTC POLYMORPHISMS CAN PREDICT THE “IN VIVO” HEMATOLOGICAL RESPONSE INDUCED BY DEFERASIROX

24. 202 BOTH AGE AND COMORBIDITIES NEGATIVELY IMPACT ON CLINICAL OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM A REAL-LIFE REGIONAL SURVEY

25. 301 IRON OVERLOAD AND IRON CHELATION THERAPY WITH DEFERASIROX IN TRANSFUSION-DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES

28. Efficacy, safety feasibility of 5-azacitidine for the treatment of myelodysplastic syndromes in the clinical practice: final results from a retrospective study in177 patients enrolled in the italian patient named program

29. Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

30. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

33. 5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM

41. Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients

42. Anagrelide in assential thronbocythemia: a retrospective study

44. Anagrelide treatment in 167 patients with essential thrombocythaemia : a retrospective study of the Italian Group GIMMC

45. Anagrelide treatment in 167 patients with assential thrombocythaemia: a retrospective study of the Italian Group GIMMC

49. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages

50. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

Catalog

Books, media, physical & digital resources